KRTX - חוב כולל להון Karuna Pharma

Karuna Therapeutics (KRTX) is a reputable developer of breakthrough schizophrenia therapies that has earned physician recognition through KarXT. This daily price chart reflects a debt-to-equity ratio of 0.01, which complements the picture of patent dominance and the pricing power to set high prices for a unique product. The business model relies on outsourcing production and testing, thereby minimizing capital expenditures.

For the long-term investor, the reliability of Karuna Therapeutics (KRTX) is determined by its ability to fund the development of non-cyclical psychotropic drugs without excessive pressure from creditors. By analyzing the total debt-to-equity ratio, which compares total liabilities to equity, one can assess the business's degree of financial autonomy and its resilience to macroeconomic shocks amid stable demand for innovative therapy.